Grabowski, Henry

Grabowski, Henry. 2004. Are the Economics of Pharmaceutical RScD Changing Productivity, Patents and PoHtical Pressures. PharmacoEconomics 22(Suppl. 2) 15-24. 

Grabowski, Henry. 2005. Encouraging the Development of New Vaccines. Health Affairs 24O) 697-700. 

Grabowski, Henry, lain Cockburn, and Genia Long. 2006. The Market for FoUow-On Biologies How Will It Evolve. Health Affairs 25(5) 1291-1301. 

Grabowski, Henry, and Margaret Kyle. 2006. Generic Competition and Market Exclusivity Periods in Pharmaceuticals. Managerial and Decision Economics, forthcoming. 

Grabowski, Henry, and C. Daniel Mullins. 1997. Pharmacy Benefit Management Cost-Effectiveness Analysis and Drug Formulary Decisions. Social Science and Medicine 45(4) 535-544. 

Grabowski, Henry, andjohn Vernon. 1986. Longer Patents for Lower Imitation Barriers The 1984 Drug Act. American Economic Review Papers and Proceedings 76(2) 195-198. 

Grabowski, Henry, and John M. Vernon. 1990. A New Look at the Return and Risks to Pharmaceutical R D. Management Science 36 804-821. 

Grabowski, Henry, and John Vernon. 1992. Brand LoyaltyEntry and Price Competition in Pharmaceuticals after the 1984 Act. Journal of Law and Economics 35(2) 331-350. 

Grabowski, Henry, and John Vernon. 1996. Longer Patents for Increased Generic Competition The Waxman-Hatch Act after One Decade. PharmacoEconomics 10 (Suppl. 2) 110-123. 

Grabowski, Henry, and John Vernon. 2000. Effective Patent Life in Pharmaceuticals. International Journal of Technology Management 19(l-2) 98-120. 

Grabowski, Henry, John M. Vernon, and Lacy Glenn Thomas. 1978. Estimating the Effects of Regulation on Innovation An International Comparative Analysis of the Pharmaceutical Industry. Journal ofEaw and Economics 21(1) 133-163. 

Grabowski, Henry, and Richard Wang. 2006. The Quantity and Quality of Worldwide New Drug Introductions 1982-2003. Health Affairs 25(2) 452M60. 

Grabowski, Henry G., "Drug Regulation and Innovation Empirical Evidence and Policy Options", American Enterprise Institute for Public Policy Research, Washington, D.C., 1976. 

DiMasi, Joseph A., Hansen, Ronald W., Grabowski, Henry G. and Lasagna, Louis, Research and Development Costs for New Drugs by Therapeutic Category A Study of the U.S. Pharmaceutical Industry, Pharmacoeconomics, February 1995. 

Henry Grabowski Duke University, Durham, North Carolina, U.S. 

Henry Grabowski John M. Vernon, Brand Loyalty, Entry and Price Competition In Pharmaceuticals After the 1984 Drug Act, 35 J. of Lnw Boon. 331-50 (Oct. 1992). 

Saha, Atanu, Henry Grabowski, Howard Birnbaum, Paul Greenberg, and Oded Bizan. 2006. Generic Competition in the U.S. Pharmaceutical Industry. International Journal of the Economics of Business 13(1) 15-38. 

Sloan, Frank A., and Henry G. Grabowski. 1997. Introduction and Overview. Social Science and Medicine 54(4) 505-510. 

DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. The Price of Innovation New Estimates of Drug Development Costs. Journal of Health Economics 22 (2003) 151-185. The researchers estimate that a new drug cost about 800 million to develop. 

There have been several studies in this area and, while I specifically refer to the Henry Grabowski work, Drug Regulation and Innovation. (9) there are others, also. This is a detailed piece of work that deserves to be a major part of our thinking on the subject. 

Henry Grabowski and John Vernon, Innovation and Structural Change in Pharmaceuticals and Biotechnology, Industrial and Corporate Change 3 (1994) 435-448. 

Henry G. Grabowski Department of Economics Duke University Durham, NC... 

The first independent attempt to estimate conventionally the benefits and costs of mandatory passive restraints was made by Richard Amould and Henry Grabowski. For the reduction in fatalities and injuries in crashes they use two sets of estimates. One set is based on a 1981 field team study of rural traffic accidents which shows, for example that fatalities are reduced by 34 percent by air bags and lap belts together, 32 percent by lap and shoulder belts together, 28 percent by passive belts, and 25 percent by air bags alone. The field study estimates are only appronmately one half of the NHTSA lab study estimates which is the other set. Arnould and Grabowski assume that 60 to 70 percent of occupants with passive belts would use them and that 0 to 20 percent of occupants with air bags would also use lap belts. Occupant protection is assumed to have no affect on chances of accidents. The 1 5 distribution of traffic accident injuries and the estimates of restraint effectiveness in crashes are used to calculate the fatalities and injuries prevented. 

Richard J. Arnould and Henry Grabowski. Auto Safety Regulation An Analysis of Market Failure The Bell Journal of Economics 12 (Spring 1981) 27-48. 

See, e.g., Henry G. Grabowski, Dmg Regulation and Innovation (AEI Evaluative Studies No. 28, 1976) William M. Wardell Louis Lasagna, Regulation and Dmg Development (AEI Evaluative Studies, 1975). 

---